Home / Transcripts / AVITA Medical, Inc. (RCEL) · November 6, 2025

AVITA Medical, Inc. (RCEL) Earnings Call Transcript

November 6, 2025

NASDAQ US Health Care Biotechnology earnings 39 min

Earnings Call Speaker Segments

Ben Atkins executive
#1

Thanks, Operator. I'd like to welcome everyone to AVITA Medical's earnings call for the third quarter of 2025. With me today are Cary Vance, our Interim Chief Executive Officer, and David O'Toole, our Chief Financial Officer. You can find today's earnings release along with the presentation on our website, www.avitamedical.com, in the Investor Relations section. Before we get started, please note that forward-looking statements are included in this call within the meaning of the Private Securities Litigation Reform Act of 1995; such statements are not promises or guarantees and carry known and unknown risks and uncertainties that might cause actual results to differ materially from any expectations expressed or implied by those forward-looking statements. For full descriptions of the risk factors, please review our most recent filings with the SEC. Any forward-looking statements made on this call reflect management's expectations as of today. I'll now hand the call over to Cary.

Cary Vance executive
#2

Good afternoon to those of you in the U.S., and good morning to everyone in Australia; it's a pleasure to be here with all of you today. Since this marks my first earnings call in the role of Interim CEO, I'd like to start by expressing how grateful I am for the chance to speak directly with our investors, our employees, and the clinical partners whose work makes AVITA's mission of transforming acute wound care achievable. I've served on AVITA's board for 2.5 years, and now, as I take on the Interim CEO position, I view the company through fresh eyes, yet also with profound conviction. AVITA's purpose matters. The people here are exceptionally talented, and the products we offer are truly transformative. My responsibility, and the focus we share collectively, is to convert that promise into steady results—where the mission, our execution, and shareholder value all come together. Let's be direct: this quarter was a difficult one. Revenue came in at roughly $17 million, which fell short of what we anticipated and mirrors the continuing effect of the reimbursement upheaval that started earlier in the year; we now anticipate full-year revenue between $70 million and $74 million, a decline from the guidance we previously gave of $76 million-$81 million. To jog your memory, back in January. Fresh Category 1 CPT codes covering RECELL usage went into effect. Since CMS never established national clinical payment rates for those codes, the task of setting payment was left to the Regional Medicare Administrative Contractors, known as MACs. The amount of time each MAC needed to establish rates and start processing claims generated ambiguity, and providers waited for confirmation that RECELL procedures would be reimbursed. Consequently, a great many providers were uncertain about when or whether claims for RECELL procedures would get paid. The encouraging part is that considerable headway has been achieved. As of today, all seven MACs have now published or confirmed acceptance of provider reimbursement rates, giving clinicians clarity and confidence regarding payment when they use RECELL; we're already observing initial indications of demand picking back up, and we anticipate that utilization will steadily return to normal over the quarters ahead; now that provider reimbursement has been mostly settled, RECELL's worth is being recognized more and more across data, adoption, payment, and policy. At the core, there is compelling real-world evidence—clinical and economic data demonstrating RECELL's capacity to optimize healing, lessen donor site burden, and reduce the length of hospital stays. Having the CPT codes for the RECELL procedure included in the CMS payment system creates a straightforward route for clinician reimbursement. Reliable reimbursement now brings back clinicians' confidence in being paid. Taken together, these layers help drive adoption as clinicians and hospitals fold RECELL into their routine practice. For instance, drawing on the robust clinical evidence, which includes data revealing a 36% reduction in hospital length of stay, one of the nation's top burn centers has now added RECELL to its treatment protocol for burns affecting under 20% total body surface area; this illustrates clearly how strong data, clinical experience, and reimbursement clarity converge to position RECELL as a standard point of care. I can also report that after RECELL GO obtained CE mark approval in Europe in September, we saw the first patient outside of the U.S. We used the device on a patient in Germany only a week ago. That represents a significant step forward, expanding who can access our RECELL technology and highlighting how relevant it is worldwide. Although this quarter showed the effects of reimbursement timing, it also was influenced by how quickly hospital Value Analysis Committee, or VAC, reviews progressed and how our commercial organization developed. Together, those things held back our short-term results, though not the strength of our strategy or the quality of what we make. During my first few weeks, I've been listening to our teams, to clinicians, to hospital partners, and to shareholders. What they've told me has been honest and consistent. Our products are outstanding, yet our results haven't always lived up to what they could achieve. RECELL, Cohealyx, and PermeaDerm genuinely change acute wound care, and now it falls to us to make sure hospitals can get these products to their clinicians and, above all, to their patients; that's where I'm focused: converting potential into steady, dependable results. Since I took the lead, we've acted fast to sharpen our commercial organization, bringing structure, territories, and accountability into line around our highest value accounts. These changes are sharpening focus, improving how well we see customer behavior, and strengthening coordination between our sales and clinical teams. With that in mind, we've taken a new look at our market opportunity so our go-to-market strategy better matches the customer behavior we observe. In the past, we've said that across all U.S. burn and trauma hospitals, the total addressable market, or TAM, for AVITA's portfolio comes to roughly $3.5 billion, and that long-term opportunity hasn't changed. What's shifted is how we understand where meaningful, scalable use happens. About 90% of our revenue today comes from roughly 200 burn centers and trauma hospitals, the core institutions that define acute wound care in the U.S; these are our most immediate and scalable growth potential. As you'll see on the slide, this focused segment accounts for $1.3 billion in targeted opportunity inside a larger $3.5 billion U.S. market. Right now we serve approximately 5% of that segment, which leaves us considerable runway for penetration and growth. Put another way, this focus lets us prioritize the hospitals and surgeons where our relationships run deepest and where we know adoption, utilization, and cross-portfolio expansion can scale most effectively. Now that this focus is set, our execution priorities for the fourth quarter are clear. First, rebuild order momentum. Now that reimbursement clarity for use of RECELL has returned, our commercial organization has a focused plan to reengage accounts that reduced their use of RECELL; this is back to basics execution. Targeted outreach, disciplined follow-up, and strong field accountability to deliver steady volume recovery. Second, drive consistent utilization of our products. Our sales and commercial teams work side by side to raise case frequency and make sure our products, RECELL, Cohealyx, and PermeaDerm, become part of routine clinical practice. Consistency in utilization creates internal champions. Champions who help expand adoption. Third, finish the transition of our commercial organization and improve forecast accuracy. Now that the commercial framework is settled, what matters most is holding ourselves accountable and equipping our teams for success. We are making intentional moves to generate steadier, more forecastable revenue expansion, rooted in a sharper grasp of how customers behave. That means shifting toward purchasing that occurs more naturally on a monthly cadence and updating our forecasting approach so it offers a truer picture of revenue ahead. Such priorities concern execution in the near term, yet they also support the longer-range strategic ambition that shapes our identity and our path to winning. Dependable utilization serves as our base. When customers use our products in a predictable way, demand becomes predictable too. Breadth across the portfolio sets us apart. RECELL, Cohealyx, and PermeaDerm, when deployed in combination, span the entire acute wound healing continuum. Improving patients' lives stays our mission. Each choice we make ought to better results for patients, clinicians, and the hospitals looking after them. We have previously covered RECELL, the cornerstone of our portfolio and the bedrock of our growth. I will now address our supplementary offerings, Cohealyx and PermeaDerm, each of which broadens our footprint throughout the acute wound healing continuum. Cohealyx keeps establishing itself as an additional engine of growth. VAC submissions are in progress at approximately 1/3 of the accounts we target. Once hospitals finish evaluating them, we anticipate that ordering will commence and grow at a steady pace across the quarters ahead.

Cary Vance executive
#3

The clinical response we're seeing from the Cohealyx I study is still favorable and lines up with what we had anticipated, and surgeons have pointed out how quickly patients become ready for grafting; we're looking at completing enrollment by the close of the year and expect to have results in the early part of next year. PermeaDerm is likewise doing well—it's a flexible biosynthetic dressing that works alongside both RECELL and Cohealyx throughout the wound healing continuum. The initial findings from our PermeaDerm -I study have us feeling good, and we should have the complete data set next year. Staying disciplined on the financial side is another leading priority. David will walk everyone through this in greater depth, but we have already made definite moves to make our operations more efficient. Our operating structure has fewer layers. Our cost base has come down, and our teams are concentrated on accomplishing more with fewer resources, even as we keep up the investments that fuel growth. Regarding the balance sheet, we obtained a waiver on our Q3 revenue covenant tied to the OrbiMed credit agreement, and we've reached an amendment that reduces the revenue covenant for Q4. Going forward, we're preserving flexibility on the balance sheet so that we retain the capital resources needed to back our operations and growth plans. An update on the financial outlook, which will include 2026 revenue and guidance, is coming in early Q1. Making sure our guidance captures both operational progress and our capital strategy. For now, we're holding onto cash and keeping cost control tight while we go on supporting our operations. Q3 represented a transition for AVITA, but it also marks the start of a more focused, disciplined, and accountable chapter for the company. The fundamentals are there. Reimbursement stability, clinical validation, and a top-tier portfolio: RECELL, Cohealyx, and PermeaDerm, which lets us address every stage of the acute wound care continuum; our attention is on execution, turning in consistent performance, rebuilding confidence, and carrying out our mission. To transform acute wound care for patients, providers, and health systems. I'm eager to keep engaging with our shareholders and to report measurable progress in the coming quarters. With that, I'll hand the call over to David.

David O'Toole executive
#4

Thanks, Cary, and good afternoon to all of you. Like Cary mentioned, AVITA's third quarter marked an inflection point — one that captured the difficulties we encountered during this year, yet also the steps we've begun taking to lay the groundwork for better results. The numbers let us down, though perhaps that wasn't unexpected, considering when reimbursement got resolved, how quickly hospital VAC reviews moved, and the changes within our commercial team. Now that these elements are settling down and our approach to costs remains solid, we head into Q4 in a stronger spot to start climbing upward in a way that's measured, intentional, and built on execution. Next, I'll take you through the financials for the quarter that closed on September 30th, 2025, and offer more background on our cost structure, liquidity, and financial priorities as we move toward Q4 and past it. On the first slide, you'll see a recap of the quarter's key financial metrics: revenue, gross margin, operating expenses, and net loss — which collectively show how dampened demand tied to reimbursement uncertainty hurt revenue, while also demonstrating what disciplined cost management, something within our control, delivered. Commercial revenue for Q3 came in at $17.1 million, versus $19.5 million during the same quarter a year ago. That's a 13% drop year over year. The main driver was the short-term reimbursement headwinds, plus additional elements such as the timing of hospital VAC reviews. That said, looking at Q4, with all seven regional MACs having now published or confirmed provider reimbursement rates, a hurdle standing in the way of providers using RECELL has been removed, which supports RECELL revenue getting back to growth. Given the third quarter's revenue, we're updating our full year 2025 revenue outlook to $70 million-$74 million, down from our earlier guidance of $76 million-$81 million; this change mirrors reimbursement normalization happening more slowly than we anticipated, together with our measured expectations for RECELL demand recovery and utilization through the end of the year. Gross profit margin for the quarter landed at 81.3%. That compares with 83.7% in Q3 2024. Product mix drove the decrease, in line with Cohealyx and PermeaDerm contributing more to total revenue, along with other inventory-related adjustments. Looking only at the RECELL franchise, gross margin stayed robust at 83.6%, and we expect that to hold going forward. As a reminder, our average sales price share for Cohealyx and PermeaDerm is 50% and 60%, respectively. Although these profit-sharing arrangements bring down overall reported gross margin as a percentage, they add incremental gross profit, and because there's limited additional SG&A expense tied to this revenue, operating profit gets stronger, as does operating cash flow. Total operating expenses were $23 million, a decrease from $30.2 million in Q3 2024. That's a $7.2 million reduction, or 24% year-over-year. The gain reflects what our cost reduction initiatives delivered and the continuing transformation of our commercial and administrative infrastructure. Breaking it down further, sales and marketing expenses fell by $3.1 million, due to lower salaries, benefits, stock-based compensation, and commissions. G&A costs came down by $2.4 million, driven by fewer employees and lower compensation-related expenses. R&D spending fell $1.7 million, largely because of reduced personnel costs and capitalizing some project expenses, particularly in-house developed software. As we shared before, after the commercial field transformation in Q2, we trimmed operating expenses by $2.5 million each quarter, which equals $10 million on an annual basis. The third quarter actuals demonstrate that reduction, and it will carry forward into upcoming quarters. Our operating loss for the quarter showed a 34% year-over-year gain, narrowing to $9.2 million from $13.8 million during the same period last year. Other expense, net came to $2.8 million, versus $1.1 million in Q3 2024. That rise mostly stems from a non-cash charge of $2.2 million tied to issuing 400,000 shares of common stock to OrbiMed under the August amendment to our loan facility, plus a $0.9 million change in the fair value of the debt. Partially offsetting these items was $0.3 million in investment income. Net loss for the quarter reached $13.2 million, or $0.46 per basic and diluted share, compared with $16.2 million, or $0.62 per basic and diluted share, in Q3 2024. That's roughly a 19% year-over-year improvement. Now on to our cash position — the next slide presents a quarterly cash waterfall showing how we keep making progress managing our cash. We entered the quarter with $15.7 million in cash, cash equivalents, and marketable securities. During August, we bolstered our balance sheet via a $13.8 million private placement, net of expenses. From that point, the waterfall chart indicates operating cash use came to $6.2 million in the third quarter, a major gain versus the $10.1 million used in Q2, which works out to almost a 40% reduction quarter over quarter; we closed September with $23.3 million in cash, cash equivalents, and marketable securities. This pattern demonstrates the concrete payoff from our cost actions and tighter cash management — things within our control — as we get back to faster revenue growth in the quarters ahead. With our cost structure solidly established, rising revenue in 2026 will let us steadily progress toward cash flow break-even. Switching to our debt facility with OrbiMed, as of September 30th, we obtained a waiver for our third quarter revenue covenant under the OrbiMed facility at no cost. In November, we signed a sixth amendment to the agreement, bringing the fourth quarter revenue covenant down to $70 million. Any further amendment to the 2026 revenue covenant, should one be needed, will be handled once we've set revenue guidance for 2026; we're additionally reviewing capital funding options to make sure AVITA Medical has enough resources to fund operations through cash flow break-even. We plan to give an update on our capital plans along with 2026 financial guidance early in Q1 of 2026. Looking forward, our financial priorities are straightforward. First, support revenue recovery as clarity around provider reimbursement stabilizes physician use of RECELL. Next, we’re taking a sharper, more focused approach to the big opportunity in front of us, so that each dollar we deploy helps move products into clinicians’ hands and to patients. Third, we’ll keep up our careful, disciplined management of cash as we work toward reaching cash flow break-even. And finally, because our cost base is now much leaner, and because we have stronger visibility into utilization behavior and improved forecasting, the company is entering a phase defined by greater focus and accountability. As we move toward financial sustainability by executing on both growth and efficiency, we stay dedicated to transparency and execution while we finish out the year and get ready to provide updated financial guidance early in Q1. With that, I’ll hand things back to Cary.

Cary Vance executive
#5

Thanks, David. In closing, although we revised our 2025 revenue projection, the steps being taken today are laying the groundwork for a stronger 2026. The right clinical science, technology, and products have always been in place at AVITA Medical. What is different at this point is our approach to operations; as reimbursement clarity comes back, we have engaged accounts, reoriented our commercial priorities, and are putting in place the structure and accountability required to achieve consistent performance. The team's resilience and focus make me proud, and I am confident that we are creating the right conditions for renewed and sustainable growth; with that, let's open the line for your questions.

Ross Osborn analyst
#6

Hi, everyone. Appreciate you letting us ask a few things. To kick things off, perhaps we could dig a bit deeper into the steps you're both taking so you can do a better job of predicting how the business will perform? Just wondering what your thinking looks like on that front with 2026 almost here.

Cary Vance executive
#7

Absolutely. Always nice to hear from you, Ross. This reaches right down to the rep level and the customer level, figuring out the way our customers use the products, and after that, in turn, the way they plan to buy those products and what sort of rhythm that follows. Our sales support structure has some truly solid modeling behind it, and we genuinely believe things will smooth out on a monthly and quarterly basis, given the several months we've now got behind us with certain of these newer products and newer customers. With the processes, the people handling them, and the leadership we've got in place today, my sense is we'll see a fair amount of improvement.

Ross Osborn analyst
#8

All right. That's excellent, and I'm happy to hear that. It's good to see the approval in Europe, and I understand that right now you're going after specific geographies. In terms of launching in a brand-new market—particularly one that's as fragmented as Europe—versus sort of bringing the U.S. business back to a steady place, how should we think about your need to balance resources?

Cary Vance executive
#9

Yes. What I'd say is that the U.S. is our main focus; on the U.S. we are laser-focused. We'll be deploying a limited set of resources, picking distributors in chosen markets, as you mentioned, and genuinely working to understand the customers in those markets and build traction. Gaining acceptance and clinical champions in those markets. Although we are committed to them, we recognize that our focus and our growth will come from the U.S. for a good long time. In the U.S., we have to get better at what we do. I don't think we'll be split or distracted in any way by what we're doing in other nations outside the U.S. It isn't a balance. It's a focus on the U.S., but with clear intention in these other countries.

Ross Osborn analyst
#10

Understood. Appreciate you answering our questions.

Josh Jennings analyst
#11

Hello. Good afternoon. Thank you for fielding the question. I was just hoping — things are still at an early stage when it comes to reimbursement normalizing and the MACs putting out finalized pricing under these new CPT codes; responses from accounts will likely span a wide range, but what's your thinking on the recovery when our accounts that have, I suppose, written policies in place are going to feel confident about reimbursement going forward? I'm sure a few might want to trial things and confirm they get reimbursed. Should we be expecting that by early 2026, we'll be back to baseline in terms of a RECELL customer base feeling confident reimbursement will come through?

Cary Vance executive
#12

Sure. Great to speak with you, Josh; what this really comes down to is just educating them about the codes and getting them to begin using the product and see that reimbursement is there, and demonstrating and proving to them that it's in place. I think that while we've been waiting for the MACs to approve and publish, we've been working in parallel. At the same time, we've been preparing our accounts so that not too much time passes between publication and when they feel confident. Still, there will be somewhat of a lag; we are working in earnest to bring them up to speed so that not just the physicians, but also those submitting the claims, know what they need to do and feel confident about it.

David O'Toole executive
#13

Hi Josh, David here. One more point to tack onto that: as we previously discussed, these claims extend all the way back to January. Every one of those claims dating back to January that remains unpaid is going to be adjudicated by the MACs. On top of that, once physicians understand that payment is coming for the claims they've already submitted as far back as January, it will build their confidence.

Josh Jennings analyst
#14

That's useful, thank you for the responses. Is there any news regarding VAC approvals for Cohealyx, how the pattern looks, and can you help us estimate the number of accounts that might be cleared to use Cohealyx when 2026 begins?

Cary Vance executive
#15

Yes. So roughly 1/3 of the accounts we have are sitting in the VAC, and around 2/3 among them are set to exit the VAC during the fourth quarter. Still, as everyone knows, schedules often slip. Suppose only a portion of that actually occurs. What we're focused on is shortening the stretch of days from approval to order placement, then from order placement to usage, plus the volume of usage. Our field teams are actively getting ready for that VAC approval, aiming to eliminate any lag connecting the approval process to ordering and utilization.

Josh Jennings analyst
#16

Got it. Just one final thing. I'm asking whether there are accounts in which RECELL, Cohealyx, and PermeaDerm can each be obtained via VACs when required. Do you notice any indications at those accounts regarding sales synergies, plus how all three get used in particular cases? That's what gives you folks confidence this portfolio could scale once RECELL reimbursement… The turbulence now is you're either passing through the eye of the storm or exiting it, and VAC approvals are arriving for 2026. We'd really like to hear about any signals from accounts that hold all three products and are putting them to use.

David O'Toole executive
#17

Yeah. Josh, I appreciate that question; it's David once more. As you're aware, RECELL has already cleared VAC at most of the accounts we currently serve. There remain a handful where we're still working through some of the trauma centers. Largely, RECELL already has approval. What we're waiting on are those VACs covering PermeaDerm and Cohealyx. Right now, we do have accounts approved for all three of those, and they're applying them to wounds. That said, it's still early, and we'll be in a position to give more detail about that. I believe it's a solid KPI to eventually share with every one of our investors and our analysts. Right now, it's a bit too soon to state what momentum we're seeing from those hospitals where all three are approved.

Josh Jennings analyst
#18

That's clear. We'll hold out for more details when you report next quarter, though I appreciate the responses and your time on these questions.

David O'Toole executive
#19

Thank you, Josh.

Sam Eiber analyst
#20

Hi there, good afternoon; Sam here, filling in for Ryan. I appreciate you taking our questions. Perhaps I could begin with how you're viewing the spending picture, considering the current state of the balance sheet and the cash situation. I suppose, is additional work required to get the organization to the right size moving forward, or are you satisfied with how the teams are currently structured?

David O'Toole executive
#21

Yes. I appreciate that question, Sam. This is David O'Toole speaking. I made a few points earlier in my prepared remarks; at this point we feel our DNA and our sales force are where they need to be for us to sustain them; we don't believe any further cost cuts are necessary. As demonstrated, we're at ease with the fact that our cash usage is going down thanks to the restructuring carried out in the second quarter, dropping from $10 million of cash used to $6 million. Our goal is to keep that momentum going, but we won't achieve it that way. Cutting alone cannot bring us to profitability. That's simply not possible. You're aware of that. Where we stand is that our cost structure is highly disciplined, very strong, and it's now positioned so that as our revenue grows, it will keep moving us toward profitability and reaching cash flow breakeven.

Chris Kallos analyst
#22

Thanks. I appreciate you fielding my question. Still on the topic of the sales force, David and Cary, I realize that reworking the way that group received incentives was a major priority at the start of this year. Are you considering altering the incentive design you currently have, or shifting toward selling a broader portfolio instead of medical detailing?

Cary Vance executive
#23

It's only been a few weeks since I stepped into this position. I'll be assembling quite a few sales compensation plans. From our standpoint, we need to be certain those plans line up with the goals we're pursuing. Beyond that, since we're now examining 2026 compensation plans, my view is that the design ought to be straightforward, equitable, and geared toward growth. That's likely everything I'm able to share at this point, though it will certainly match what we're aiming to achieve in the field.

Chris Kallos analyst
#24

Yeah, honestly, putting those questions forward right now might be a bit unfair. Perhaps this one's for David. Given the guidance as it stands, is any of that catch-up backlog tied to the reimbursement payments backlog being factored in?

David O'Toole executive
#25

Hi, Chris. It's great to speak with you, and I appreciate you asking. As always, I'm looking forward to seeing you in Australia next week.

Chris Kallos analyst
#26

Same here.

David O'Toole executive
#27

With the MACs now publishing and their prices available, this won't flip on like a light switch; some time will be needed. We're going out and teaching our clients and our customers that it has occurred and that payment will come their way. Confidence among those providers has to be rebuilt so they'll use RECELL and trust that they'll be reimbursed. Our guidance for the remainder of this year stems largely from the reduced revenue in Q3 and, in fact, from the reduced revenue in January of this year brought about by the reimbursement headwinds. As stated during our prepared remarks, a full update to our revenue guidance for 2026 will be provided in early 2026. At that time, everyone will see more clearly what 2026 will look like.

Chris Kallos analyst
#28

Okay. David, has the moment arrived too soon for us to discuss when you might reach breakeven, or the schedule for that?

David O'Toole executive
#29

Right now, yes, it has. Cary has now been working here for 3 or 4 weeks. Everyone is essentially starting over. Early in the year, we'll be in a position to share additional detail on that, along with the entire 2026 revenue guidance.

Chris Kallos analyst
#30

That's everything I wanted to ask. Thanks, David.

David O'Toole executive
#31

Appreciate it, Chris.

Cary Vance executive
#32

I appreciate that, operator. And I want to express my gratitude to each of you for the questions you've raised, for being engaged, and for your backing. The term headwinds has come up rather often, I'd say, in what we've shared and in a number of these answers. What strikes me as notable regarding this company is that the exact factors that have been working against us will shift to working in our favor and will drive us onward. Occasionally a business faces challenges such as recalls and similar matters that simply bring them to a halt. In our situation, I'd say, if you consider the VAC committees that have slowed us somewhat, those very clearances will push us ahead. The identical dynamic applies to uncertainty around reimbursement. Once certainty arrives, it will carry us forward. That same pattern holds for the commercial organization. Once you get that optimized, it genuinely moves you ahead. When you receive data showing that using and buying our products saves money and generates money, those sorts of things advance you both financially and clinically. The evidence is really compelling that AVITA and our products will make a growth move in 2026. Given that, I'm eager to talk about that further progress in the weeks and months to come with every one of you. Thank you.

Operator operator
#33

Thank you. This concludes today's conference. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AVITA Medical, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AVITA Medical, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.